Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Milan
Clinical trial register · Italy

Clinical Trials in Milan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6791 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:19 UTC
6791
Studies in scope
all four open statuses
4079
Recruiting now
open to new participants
1019
Lead sponsors
across recruiting studies
Top sites
Milan 31 Florence 11 Verona 10 Roma 9 Naples 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS San Raffaele160 AstraZeneca137 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Novartis Pharmaceuticals73 Clear sponsor filter
Site location
Milan31 Florence11 Verona10 Roma9 Naples8
All 65 locations
Target enrolment
to

Trials with a site in Milan

31 of 6791 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Amgen
Phase 3
406
Ferrara, Milan, San Donato Milanese, Torino
2026-03-23
Recruiting
Amgen
Phase 3
750
Foggia, Milan, Modena, Orbassano, Peschiera del Garda, Rozzano, Trento
2025-11-28
Active, closed
Amgen
Phase 3
350
Bari, Bergamo, Meldola (FC), Milan, Roma, Verona
2025-08-18
Recruiting
Amgen
Phase 1
434
Milan, Pisa, Verona
2025-07-31
Recruiting
Amgen
Phase 3
12,800
Arzignano, Caserta, Ceccano, Chieti, Foggia, L’Aquila, Milan, Padova
2025-07-25
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Milan, Rozzano, Turin
2025-07-16
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Bari, Bergamo, Brescia, Cortona AR, Foggia, Forlì, Milan, Naples
2025-06-25
Active, closed
Amgen
Phase 1
29
Candiolo to, Meldola (FC), Milan
2025-05-16
Active, closed
Amgen
Phase 3
1,105
Bologna, Chieti, Florence, Milan, Palermo
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Bologna, Chieti, Florence, Milan, Palermo, Pisa, Roma
2025-03-12
Recruiting
Amgen
Phase 3
844
Udine, Rome, Milan, Turin, Verona, Pisa, Reggio Emilia
2025-02-25
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bologna, Milan, Naples, Rome
2025-01-13
Active, closed
Amgen
Phase 3
707
Foggia, Gallipoli, Genova, Milan, Orbassano, Trento
2024-12-09
Active, closed
Amgen
Phase 2
409
Bari, Bologna, Chieti, Milan
2024-11-07
Active, closed
Amgen
Phase 1
49
Alessandria, Milan, Rozzano (MI), Verona
2024-09-17
Active, closed
Amgen
Phase 3
315
Cona, Cremona, Milan, Naples, Ravenna, Sondrio, Terni
2024-09-09
Recruiting
Amgen
Phase 3
450
Brescia, Castellana Grotte, Florence, Foggia, Genova, Meldola FC, Milan, Naples
2024-07-17
Active, closed
Amgen
Phase 3
563
Bari, Milan, Verona
2024-06-05
Active, closed
Amgen
Phase 1/2
94
Milan, Pisa, Varese
2024-05-30
Active, closed
Amgen
Phase 1
120
Milan, Rozzano MI, Verona
2024-05-29
Active, closed
Amgen
Phase 3
434
Reggio Emilia, Udine, Rome, Milan, Novara, Florence, Verona, Catania
2024-04-08
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Aviano PN, Milan, Orbassano, Padova, Perugia, Pisa, Reggio Emilia, Rozzano MI
2024-02-20
Recruiting
Amgen
Phase 3
750
Bari, Brescia, Candiolo, Catania, Florence, Meldola (FC), Milan, Monza (MB)
2023-11-16
Recruiting
Amgen
Phase 3
60
Chieti, Genova, Milan, Roma
2022-03-17
Active, closed
Amgen
Phase 3
303
Bari, Bergamo, Bologna, Genova, Lecce, Mestre (VE), Milan, Naples
2021-11-02
Recruiting
Amgen
Phase 3
60
Chieti, Genova, Milan, Roma
2021-09-09
Active, closed
Amgen
Phase 1/2
181
Bergamo, Bologna, Brescia, Catania, Milan, Naples, Roma
2021-01-04
Active, closed
Amgen
Phase 3
135
Florence, Milan, Pisa, Reggio Emilia, Torino, Verona
2020-12-04
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Milan, Pavia, Rome
2020-10-15
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Milan, Pisa, Verona
2019-12-17
Active, closed
Amgen
Phase 3
457
Milan, Palermo, Pavia, Roma
2019-07-19
Rows per page Showing 1–31 of 31
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-italy/city/milan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,791 studies in total at the last sync on 11 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 31 of those studies with a site in Milan that also match the filters currently applied.

How many clinical trials are recruiting in Milan?

11 of the 31 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Milan), 31 studies
PhaseStudiesRecruitingShare
Phase 322971%
Phase 15116.1%
Phase 1/2206.5%
Phase 2216.5%

Most active sponsors

Lead sponsors with the most studies (Milan)
Lead sponsorStudiesRecruiting
Amgen3111
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.